Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)
CUSIP: 98943L107
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock,$0.001 par value per share
- Shares outstanding
- 72,096,078
- Total 13F shares
- 82,228,758
- Share change
- +15,435,501
- Total reported value
- $2,319,672,532
- Put/Call ratio
- 33%
- Price per share
- $28.21
- Number of holders
- 131
- Value change
- +$442,954,370
- Number of buys
- 93
- Number of sells
- 36
Quarterly Holders Quick Answers
What is CUSIP 98943L107?
CUSIP 98943L107 identifies ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98943L107:
Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP |
13F
|
Company |
13%
|
9,199,973
|
$158,239,536 | — | 31 Mar 2023 | |
| FMR LLC |
13F
|
Company |
12%
|
8,912,751
|
$153,299,317 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.9%
|
4,240,615
|
$72,938,578 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
4.7%
|
3,417,467
|
$58,780,432 | — | 31 Mar 2023 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
4.7%
|
3,360,329
|
$57,797,659 | — | 31 Mar 2023 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
4.5%
|
3,227,000
|
$55,504,400 | — | 31 Mar 2023 | |
| Capital International Investors |
13F
|
Company |
4.3%
|
3,127,758
|
$53,797,438 | — | 31 Mar 2023 | |
| Avidity Partners Management LP |
13F
|
Company |
4.1%
|
2,929,300
|
$50,383,960 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
3.9%
|
2,832,023
|
$48,710,796 | — | 31 Mar 2023 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3.1%
|
2,200,169
|
$37,844,000 | — | 31 Mar 2023 | |
| Woodline Partners LP |
13F
|
Company |
3%
|
2,165,551
|
$37,247,477 | — | 31 Mar 2023 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.8%
|
2,010,409
|
$34,580,000 | — | 31 Mar 2023 | |
| Decheng Capital Management III (Cayman), LLC |
13F
|
Company |
2.5%
|
1,824,583
|
$31,382,828 | — | 31 Mar 2023 | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
|
Company |
2.3%
|
1,632,289
|
$28,075,371 | — | 31 Mar 2023 | |
| Anthony Y. Sun |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
2,592,141
|
$26,672,095 | — | 04 Apr 2022 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.1%
|
1,486,998
|
$25,576,366 | — | 31 Mar 2023 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
2%
|
1,439,062
|
$24,751,866 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.8%
|
1,329,993
|
$22,875,879 | — | 31 Mar 2023 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.8%
|
1,290,296
|
$22,193,091 | — | 31 Mar 2023 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
1.6%
|
1,128,920
|
$19,417,424 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
895,925
|
$15,409,916 | — | 31 Mar 2023 | |
| Iris Roth |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
350,000
mixed-class rows
|
$14,760,704 | — | 01 Mar 2023 | |
| Capital World Investors |
13F
|
Company |
0.95%
|
683,000
|
$11,747,600 | — | 31 Mar 2023 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.83%
|
600,000
|
$10,320,000 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.59%
|
426,871
|
$7,342,180 | — | 31 Mar 2023 | |
| Verition Fund Management LLC |
13F
|
Company |
0.54%
|
390,582
|
$6,718,010 | — | 31 Mar 2023 | |
| Allspring Global Investments Holdings, LLC |
13F
|
Company |
0.5%
|
360,151
|
$6,194,595 | — | 31 Mar 2023 | |
| NORGES BANK |
13F
|
Company |
0.47%
|
337,642
|
$5,807,442 | — | 31 Mar 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.46%
|
333,568
|
$5,737,370 | — | 31 Mar 2023 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.45%
|
322,797
|
$5,551,631 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.42%
|
300,290
|
$5,164,988 | — | 31 Mar 2023 | |
| Mayo Clinic |
13F
|
Company |
0.41%
|
297,143
|
$5,110,860 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.38%
|
271,264
|
$4,665,742 | — | 31 Mar 2023 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.37%
|
267,305
|
$4,597,646 | — | 31 Mar 2023 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.34%
|
248,440
|
$4,273,168 | — | 31 Mar 2023 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
0.32%
|
234,000
|
$4,024,800 | — | 31 Mar 2023 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.32%
|
228,337
|
$3,927,396 | — | 31 Mar 2023 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.29%
|
208,918
|
$3,593,390 | — | 31 Mar 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.28%
|
203,946
|
$3,507,871 | — | 31 Mar 2023 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.27%
|
194,933
|
$3,352,848 | — | 31 Mar 2023 | |
| CITIGROUP INC |
13F
|
Company |
0.26%
|
188,719
|
$3,245,968 | — | 31 Mar 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
155,552
|
$2,675,494 | — | 31 Mar 2023 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
147,923
|
$2,544,276 | — | 31 Mar 2023 | |
| Alexis Pinto |
3/4/5
|
Chief Legal Officer |
—
mixed-class rows
|
60,729
mixed-class rows
|
$2,068,615 | — | 10 Feb 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.16%
|
114,511
|
$1,970,000 | — | 31 Mar 2023 | |
| Swiss National Bank |
13F
|
Company |
0.14%
|
98,500
|
$1,694,200 | — | 31 Mar 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.12%
|
89,964
|
$1,547,380 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
83,409
|
$1,434,635 | — | 31 Mar 2023 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.11%
|
82,707
|
$1,422,560 | — | 31 Mar 2023 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.11%
|
79,963
|
$1,375,364 | — | 31 Mar 2023 |
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q2 2023
As of 30 Jun 2023,
Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
82,228,758 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, FMR LLC, EVENTIDE ASSET MANAGEMENT, LLC, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, Capital International Investors, PRICE T ROWE ASSOCIATES INC /MD/, Avidity Partners Management LP, and CITADEL ADVISORS LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
108
Q2 2023 holders
131
Holder diff
23
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.